THALES
8.12.2021 08:02:06 CET | Business Wire | Press release
Gireve, the leading B2B digital platform for electric mobility, and Thales, leader in digital security, have collaborated to provide a simple and secure ´Plug & Charge´ access and billing system. The joint solution, based on the Thales Trusted Key Manager and Gireve’s intermediation platform, improves the driver experience, builds trust in a multi players’ ecosystem and also helps meet the ISO 15118 International standard.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211207006154/en/
While the EV market rapidly expands, convenient access to charging networks becomes a priority. The current charging network is still very fragmented, often proprietary and not available in enough places. A global standardized and interoperable solution is needed as well as an improved management of the delivery of electricity.
Today each e-Mobility Service Provider (eMSP) offers EV drivers an RFID card to access and start a charging session. Gireve and Thales have partnered to create a harmonized ´Plug & Charge´ solution to simplify the experience and ensure the highest level of security for all EV market players.
Drivers simply plug their electric car into any ISO 15118-compatible charging station, without using a physical card, and the billing is automatically associated to the subscription managed for them. As a result drivers can then freely choose an e-Mobility Service Provider and access a wider number of charging stations; while benefitting from a secure automated charging and digital payment experience.
The solution delivers unique credential certificates to each actor in the system from driver to vehicle and charging station. The system, based on Thales Trusted Key Manager then ensures the secure and instant mutual authentication between these actors. The solution also verifies that the right credentials are securely generated and distributed from the right e-Mobility Provider to the associated vehicle and user. The result – a simpler and more secure EV charging experience.
This mutual authentication and secure credentials management also set the basis of a trusted environment for coming smart grid deployments. As the EV market is expected to boom in the coming years, so does electricity need. Indeed, such increasing needs will require improved and safe energy management and delivery to address power peaks demand.
“ For almost 10 years, Gireve has been a central trusted third party for B2B players in the charging sector. Together with Thales, we are confident our solution addresses key challenges to back up the sustainable success of the EV ecosystem. Our joint efforts are all about facilitating energy access, bringing trust through cybersecurity and boosting drivers’ adoption with improved usage.” Eric Plaquet, CEO at Gireve
“Gireve offered Thales a great opportunity to deploy its field-proven expertise in strong authentication and cybersecurity to the smart charging market. Our partnership supports the sustainable e-mobility sector, by smoothing EV charging access and by creating the trust the sector needs to succeed. Looking forward, our collaboration may unleash further use cases to support smart grid development with more efficient energy management.” Christine Caviglioli, Vice President Automotive at Thales
1
https://www.delta-ee.com/downloads/1-research-downloads/2830-whitepaper-ev-forecasts-84-million-evs-on-european-roads-by-2030.html
2
ISO 15118 is an international standard that outlines the digital communication protocol that an electric vehicle (EV) and charging station should use to recharge the EV’s high-voltage battery.
About Thales
Thales (Euronext Paris: HO) is a global leader in advanced technologies, investing in digital and “deep tech” innovations – connectivity, big data, artificial intelligence, cybersecurity and quantum computing – to build a confident future crucial for the development of our societies. The Group provides its customers – businesses, organisations and governments – in the defense, aeronautics, space, transport, and digital identity and security domains with solutions, services and products that help them fulfil their critical role, consideration for the individual being the driving force behind all decisions.
Thales has 81,000 employees in 68 countries. In 2020 the Group generated sales of €17 billion.
About GIREVE
Combining Market Place, Transactions Processing, and Data Management technologies, GIREVE is the leading B-to-B digital platform for electric recharging, offering the first coverage in terms of number of charge points in Europe. The company manages 3,800 contracts between 277 players in 32 countries and references more than 220,000 charge points, including 149,000 open to roaming.
For almost 10 years, GIREVE has been a central trusted third party for B-to-B players in the charging sector, handling negotiations and transactions independently, securely, according to transparent rules, and in compliance with regulations.
PLEASE VISIT
Thales Group
Market page
View source version on businesswire.com: https://www.businesswire.com/news/home/20211207006154/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom